a live attenuated chimeric JE vaccine
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Dec 1, 2013 → Jul 1, 2015
NCT ID
NCT02602652About a live attenuated chimeric JE vaccine
a live attenuated chimeric JE vaccine is a pre-clinical stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02602652. Target conditions include Japanese Encephalitis.
What happened to similar drugs?
3 of 20 similar drugs in Japanese Encephalitis were approved
Approved (3) Terminated (0) Active (17)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02602652 | Pre-clinical | Completed |
Competing Products
20 competing products in Japanese Encephalitis